Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland
March 17, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, March 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress
September 23, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...
Alimera Sciences Obtains Reimbursement Approval for ILUVIEN® Use in Non-Infectious Posterior Uveitis in Scotland
September 08, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...